Stay updated on Safety and Tolerability of ABBV-467 in R/R Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Safety and Tolerability of ABBV-467 in R/R Multiple Myeloma Clinical Trial page.

Latest updates to the Safety and Tolerability of ABBV-467 in R/R Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe revision history shows an update from v3.3.1 to v3.3.2 with no changes to study content or visible page details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedA new revision version v3.3.1 has been added to the Study Record Versions, and revision v3.2.0 has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the general notice about government funding and NIH operating status from the page, which does not affect trial data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check43 days agoChange DetectedThe page shows only version history entries for NCT04178902, and there are no substantive additions or deletions to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference12%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%

Stay in the know with updates to Safety and Tolerability of ABBV-467 in R/R Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Tolerability of ABBV-467 in R/R Multiple Myeloma Clinical Trial page.